The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1285
ISSUE1285
May 5, 2008
Natalizumab (Tysabri) for Crohn's Disease
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Natalizumab (Tysabri) for Crohn's Disease
May 5, 2008 (Issue: 1285)
Natalizumab (Tysabri - Elan and Biogen) is a monoclonal antibody approved for induction and maintenance treatment of moderate to severe Crohn's disease (CD) refractory to conventional therapies and inhibitors of tumor necrosis factor (TNF)....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
